Revisiting safety of minocycline as neuroprotection in Huntington's disease

Mov Disord. 2007 Jan 15;22(2):292. doi: 10.1002/mds.21199.
No abstract available

Publication types

  • Clinical Trial
  • Letter

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Anti-Bacterial Agents / adverse effects*
  • Anti-Bacterial Agents / therapeutic use*
  • Humans
  • Huntington Disease / drug therapy*
  • Hyperpigmentation / chemically induced*
  • Hyperpigmentation / epidemiology
  • Middle Aged
  • Minocycline / adverse effects*
  • Minocycline / therapeutic use*
  • Neuroprotective Agents / adverse effects*
  • Neuroprotective Agents / therapeutic use*
  • Prevalence

Substances

  • Anti-Bacterial Agents
  • Neuroprotective Agents
  • Minocycline